B. Riley Wealth Management Inc. purchased a new position in Mylan NV (NASDAQ:MYL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,311 shares of the company’s stock, valued at approximately $268,000.
A number of other institutional investors have also bought and sold shares of MYL. Bank of New York Mellon Corp grew its position in Mylan by 32.1% in the second quarter. Bank of New York Mellon Corp now owns 9,408,218 shares of the company’s stock worth $340,012,000 after buying an additional 2,284,545 shares during the last quarter. Bank of Montreal Can grew its position in Mylan by 605.0% during the 3rd quarter. Bank of Montreal Can now owns 2,193,264 shares of the company’s stock worth $80,274,000 after purchasing an additional 1,882,157 shares in the last quarter. Orbimed Advisors LLC grew its position in Mylan by 77.7% during the 2nd quarter. Orbimed Advisors LLC now owns 3,702,800 shares of the company’s stock worth $133,819,000 after purchasing an additional 1,618,500 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Mylan by 14.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,132,430 shares of the company’s stock worth $185,499,000 after purchasing an additional 644,643 shares in the last quarter. Finally, Pictet Asset Management Ltd. purchased a new position in Mylan during the 3rd quarter worth approximately $22,682,000. Hedge funds and other institutional investors own 82.16% of the company’s stock.
Several equities analysts have weighed in on the stock. ValuEngine cut shares of Mylan from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Cantor Fitzgerald reiterated a “hold” rating and set a $41.00 price objective on shares of Mylan in a research report on Tuesday, November 20th. Argus upgraded shares of Mylan from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research report on Thursday, November 15th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Mylan and gave the stock a “buy” rating in a research report on Tuesday, November 6th. Finally, Wells Fargo & Co upgraded shares of Mylan from a “market perform” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Tuesday, November 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $46.56.
Shares of NASDAQ:MYL opened at $26.46 on Friday. The firm has a market cap of $14.29 billion, a price-to-earnings ratio of 5.80, a P/E/G ratio of 0.92 and a beta of 1.49. Mylan NV has a 12-month low of $26.18 and a 12-month high of $47.82. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 5th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.06. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.91 billion. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The company’s revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter last year, the business posted $1.10 EPS. Equities analysts forecast that Mylan NV will post 4.66 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “B. Riley Wealth Management Inc. Invests $268,000 in Mylan NV (MYL) Stock” was published by Modern Readers and is the sole property of of Modern Readers. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.modernreaders.com/news/2018/12/22/b-riley-wealth-management-inc-invests-268000-in-mylan-nv-myl-stock.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Mylan Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan and related companies with MarketBeat.com’s FREE daily email newsletter.